Results 21 to 30 of about 17,592 (206)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Léa Darnaud, Benoit Blanchet, Jérôme Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka   +15 more
doaj   +1 more source

Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population

Technology in Cancer Research & Treatment, 2022
Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently.
Yusi Zhang MS, Wenlin Chen MD, Shuanglong Chen MS, Qingmo Yang MD, Zhong Ouyang MD   +4 more
doaj   +1 more source

MIMA study - Palbociclib

, 2022
spatially registered images of multiplex IHC staining of MMTV-PyMT mammary carcinoma tissue three days after local Palbociclib drug delivery. Drug release is from the bottom to the top. 
Zuzana Tatarova (12507553)
core   +1 more source

Combination of palbociclib and radiotherapy for glioblastoma

, 2017
The cyclin-dependent kinase inhibitor, palbociclib has shown compelling efficacy in breast cancer patients. Several pre-clinical studies of glioblastoma (GBM) have also shown palbociclib to be efficacious.
Mustafa Khasraw, Bryan Day, Sylvia A Chung, Kerrie L McDonald, Terrance Johns, Swapna Joshi, Shane Whittaker, Daniel Madani   +7 more
core   +2 more sources

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial

, 2021
IMPORTANCE: The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor–positive, ERBB2-negative advanced breast cancer ...
Di Cosimo, Serena, Aguirre, Elena, Schneeweiss, Andreas, Sampayo-Cordero, Miguel, Amillano, Kepa, Bellet, Meritxell, Albanell, Joan, Schmid, Peter, Ruíz-Borrego, Manuel, Wheatley, Duncan, Zamora, Pilar, Gavilá, Joaquín, Marmé, Frederik, PARSIFAL Steering Committee and Trial Investigators, Llombart-Cussac, Antonio, Malfettone, Andrea, Dalenc, Florence, Gligorov, Joseph, Gil-Gil, Miguel, Pérez-García, José Manuel, Cortés, Javier, Martínez-de Dueñas, Eduardo   +21 more
core   +2 more sources

Population Pharmacokinetics of Palbociclib in a Real-World Situation

, 2021
Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer.
Audrey Hennequin, Sivia Ilie, Antonin Schmitt, Bernard Royer, Siavoshe Ayati, Didier Mayeur, Sylvain Ladoire, Jean-David Fumet, Isabelle Desmoulins, Courèche Kaderbhaï   +9 more
core   +1 more source

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

Breast, 2021
Background: This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC).
R.K. Ismail, J. van Breeschoten, M.W.J.M. Wouters, M. van Dartel, S. van der Flier, A.K.L. Reyners, P. de Graeff, A.M.G. Pasmooij, A. de Boer, K.E. Broekman, D.L. Hilarius   +10 more
doaj   +1 more source

Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma

BMC Medicine, 2022
Background Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC).
Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li, Zhiyuan Zhang, Rong Zhou   +11 more
doaj   +1 more source

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells

Cells, 2021
Resistance to CDK4/6 inhibitors (CDKis) is emerging as a clinical challenge. Identification of the factors contributing to CDKi resistance, with mechanistic insight, is of pivotal significance.
Qiong Cheng, Zhikun Ma, Yujie Shi, Amanda B. Parris, Lingfei Kong, Xiaohe Yang   +5 more
doaj   +1 more source

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

Patient Preference and Adherence, 2023
Nicole M Engel-Nitz,1 Mary G Johnson,1 Michael P Johnson,1 Ashley S Cha-Silva,2 Samantha K Kurosky,2 Xianchen Liu2 1Optum, Eden Prairie, MN, 55344, USA; 2Pfizer Inc, New York, NY, 10017, USACorrespondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences,
Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X   +5 more
doaj